A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

A European regulatory committee now recommends approval of the Alzheimer's treatment lecanemab a few months after rejecting ...

Biogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...

Eisai Company Limited (4523.T) has reported a modest revenue increase in its Q2 Fiscal 2024 earnings call, with significant developments in its Alzheimer's disease treatments. The pharmaceutical ...

Analysis of Leqembi's commercial potential and market outlook, with a focus on growth projections and investment ...

Eisai Company Limited (4523.T) has reported a modest revenue increase in its Q2 Fiscal 2024 earnings call, with significant developments in its Alzheimer's disease treatments. The pharmaceutical giant ...

Eisai Company Limited (ESALY (OTC:ESAIY)) has reported a modest revenue growth of 3% year-on-year in its Q2 Fiscal 2024 earnings call, totaling JPY 385 billion. The pharmaceutical segment saw a 5% ...

Eisai Company Limited (ESALY (OTC:ESAIY)) has reported a modest revenue growth of 3% year-on-year in its Q2 Fiscal 2024 earnings call, totaling JPY 385 billion. The pharmaceutical segment saw a 5% ...